A novel topical treatment, clascoterone, is showing significant promise in combating male pattern baldness, offering a potential breakthrough after three decades without major advancements. Originally developed for acne, this twice-daily lotion has demonstrated remarkable efficacy in two new clinical trials, prompting dermatologists to label it a 'gamechanger' and causing shares in its developer, Cosmo Pharmaceuticals, to soar.

Male pattern baldness, scientifically known as androgenetic alopecia, is the most common form of hair loss, affecting approximately 6.5 million men in the UK. It is characterized by a receding hairline or a bald patch on the top of the head and often has a hereditary component. The root cause lies with dihydrotestosterone (DHT), a derivative of testosterone, which progressively shrinks genetically sensitive hair follicles until the hair growth mechanism ceases entirely.

Current treatments for male pattern baldness include minoxidil (brand name Regaine), available as a foam or liquid, which is believed to enhance blood flow to hair follicles. However, its effectiveness is limited, with 40 to 50 percent of men experiencing little benefit, and any gains are lost upon cessation of treatment. Other options, such as finasteride and dutasteride, are oral medications that lower DHT levels throughout the body. While effective, they come with potential side-effects like decreased libido, which many men find off-putting.

Clascoterone distinguishes itself by offering a different approach: it directly blocks the action of DHT within the hair follicle itself, circumventing body-wide side effects. The formulation used for baldness is five times stronger than its acne counterpart, Winlevi, which targets hormone effects in the skin's oil glands to reduce inflammation and oil production.

The two pivotal trials, SCALP 1 and SCALP 2, involved 1,465 men across Europe and the US, making them the largest hair-loss studies for a topical treatment to date. Participants were administered either clascoterone lotion or a placebo. Hair growth was meticulously measured by photographing and counting hairs in a small, tattooed scalp area. After six months, one study reported an impressive 539 percent improvement in hair count among those using clascoterone, while the other showed a 168 percent improvement. Crucially, men in the placebo groups did not experience similar benefits, and side effects for clascoterone were limited to mild skin reactions like redness or itching, which also occurred in the placebo group.

Professor Maria Hordinsky, chair of dermatology at the University of Minnesota and lead researcher, highlighted the significance of the minimal side effects. "Concerns about libido, erectile function, and mood are significant barriers for many men considering oral finasteride or dutasteride," she noted. Professor Hordinsky added that the prospect of a novel, biologically targeted, well-tolerated topical therapy is "genuinely exciting" given the number of affected men who avoid current options.

While Professor Desmond Tobin of University College Dublin hailed the results as a "very significant breakthrough," he cautioned that continuous use is essential, as stopping the treatment would likely restart the balding process. Spencer Kobren, founder of the American Hair Loss Association, advised caution in interpreting the 539 percent figure, clarifying that it indicates superior performance over placebo in a measured area rather than a fivefold increase in hair. However, Professor Hordinsky confirmed that patients observed visible differences, reporting fuller coverage and better density.

Like most hair-loss treatments, clascoterone is most effective in early-stage thinning rather than complete baldness. Ideal candidates include younger men with initial hair loss, individuals who have shied away from finasteride due to side-effect concerns, and those who haven't responded to minoxidil or desire a treatment that targets the underlying cause directly.

The treatment is not yet available and is expected to be prescription-only. Cosmo Pharmaceuticals intends to file for regulatory approval in the US and Europe in the spring, potentially making it accessible in UK pharmacies later this year. Kobren issued a warning about unregulated 'grey-market' versions that often emerge when treatments gain media attention before official availability, urging consumers to wait for the genuine product.

Beyond clascoterone, other hair-loss treatments are in development. KX-826, another rub-on lotion that blocks DHT, is in final trials but has not yet matched clascoterone's efficacy. GT20029, a more advanced lotion, aims to break down the androgen receptor on hair follicles, showing promise in early trials but requiring more extensive studies. Additionally, JAK inhibitors, tablets used for rheumatoid arthritis (like ritlecitinib, approved by the NHS for alopecia areata in 2024), have shown potential in stimulating hair growth for certain alopecia conditions. Even stem cells extracted from umbilical cords are being investigated, with lab experiments suggesting their capacity to promote healthy new hair growth, leading to an ongoing trial involving 100 men and women in the US. For the first time in a generation, men concerned about thinning hair may soon have genuinely new and effective options to consider.